T-DXd significantly improves progression-free and overall survival compared to T-DM1 in HER2-positive metastatic breast cancer, with a favorable safety profile. Real-world data show T-DXd's ...
Raludotatug deruxtecan (R-DXd) received FDA breakthrough therapy designation for CDH6-expressing platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers. Phase 1 study demonstrated a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results